Exogenous administration of immunomodulatory therapies in hematopoietic cell transplantation: An infectious diseases perspective

Current Opinion in Infectious Diseases

Volumn 18, Issue 4, 2005, Pages 352-358

  Brown, Janice M Y ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Chimerism; Graft versus host disease; Graft versus tumor; Hematopoietic cell transplantation; Immune reconstitution; Immunomodulation; Lymphocyte specific monoclonal antibodies

Indexed keywords

ALEMTUZUMAB; AMPHOTERICIN; ANTIFUNGAL AGENT; ANTIVIRUS AGENT; BASILIXIMAB; CALCINEURIN INHIBITOR; CASPOFUNGIN; CIDOFOVIR; CORTICOSTEROID; CYCLOSPORIN A; DACLIZUMAB; ECHINOCANDIN; FLUCONAZOLE; FOSCARNET; GANCICLOVIR; IMMUNOMODULATING AGENT; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; LYMPHOCYTE ANTIBODY; METHOTREXATE; MONOCLONAL ANTIBODY; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PENTOSTATIN; PURINE DERIVATIVE; RAPAMYCIN; RITUXIMAB; TACROLIMUS; UNINDEXED DRUG; VALGANCICLOVIR; VORICONAZOLE;

ASEPTIC MENINGITIS; BACTERIAL INFECTION; BLOOD TOXICITY; CHICKENPOX; CHIMERA; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL TRIAL; CORRELATION ANALYSIS; CYTOMEGALOVIRUS INFECTION; DISEASE ACTIVITY; DISEASE SEVERITY; DRUG ERUPTION; DRUG FATALITY; DRUG FEVER; EARLY DIAGNOSIS; GRAFT VERSUS HOST REACTION; GRAFT VERSUS LEUKEMIA EFFECT; HEADACHE; HEMATOLOGIC MALIGNANCY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEMOLYTIC UREMIC SYNDROME; HEPATITIS B; HUMAN; HYPOGAMMAGLOBULINEMIA; IMMUNE RESPONSE; IMMUNE SYSTEM; IMMUNITY; IMMUNOMODULATION; INFECTION; INFLUENZA; LIVER TOXICITY; LYMPHOCYTOPENIA; NEUROTOXICITY; NEUTROPENIA; OPTIC NERVE DISEASE; PATHOGENESIS; PLEURISY; PNEUMONIA; REVIEW; SEIZURE; SERUM SICKNESS; THROMBOCYTOPENIC PURPURA; TREATMENT OUTCOME; UVEITIS; VASCULITIS;

EID: 22544437611     PISSN: 09517375     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.qco.0000172700.98149.60     Document Type: Review

References (83)

1. Robak T. Monoclonal antibodies in the treatment of chronic lymphoid leukemias. Leuk Lymphoma 2004; 45:205-219.
2. Wasil T, Rai KR, Mehrotra B. The role of monoclonal antibodies in stem cell transplantation. Semin Oncol 2004; 31:83-89.
3. Canninga-van Dijk MR, van der Straaten HM, Fijnheer R, et al. Anti-CD20 monoclonal antibody treatment in 6 patients with therapy-refractory chronic graft-versus-host disease. Blood 2004; 104:2603-2606.
4. Tsutsumi Y, Kawamura T, Saitoh S, et al. Hepatitis B virus reactivation in a case of non-Hodgkin's lymphoma treated with chemotherapy and rituximab: necessity of prophylaxis for hepatitis B virus reactivation in rituximab therapy. Leuk Lymphoma 2004; 45:627-629.
5. Tsutsumi Y, Tanaka J, Kawamura T, et al. Possible efficacy of lamivudine treatment to prevent hepatitis B virus reactivation due to rituximab therapy in a patient with non-Hodgkin's lymphoma. Ann Hematol 2004; 83: 58-60.
6. Brugger W, Hirsch J, Grunebach F, et al. Rituximab consolidation after high-dose chemotherapy and autologous blood stem cell transplantation in follicular and mantle cell lymphoma: a prospective, multicenter phase II study. Ann Oncol 2004; 15:1691-1698.
7. Shimoni A, Hardan I, Avigdor A, et al. Rituximab reduces relapse risk after allogeneic and autologous stem cell transplantation in patients with high-risk aggressive non-Hodgkin's lymphoma. Br J Haematol 2003; 122: 457-464.
8. Goldberg SL, Pecora AL, Alter RS, et al. Unusual viral infections (progressive multifocal leukoencephalopathy and cytomegalovirus disease) after high-dose chemotherapy with autologous blood stem cell rescue and peritransplantation rituximab. Blood 2002; 15:1486-1488.
9. Matteucci P, Magni M, Di Nicola M, et al. Leukoencephalopathy and papovavirus infection after treatment with chemotherapy and anti-CD20 monoclonal antibody. Blood 2002; 1:1104-1105.
10. Ladetto M, Zallio F, Vallet S, et al. Concurrent administration of high-dose chemotherapy and rituximab is a feasible and effective chemo/immunotherapy for patients with high-risk non-Hodgkin's Lymphoma. Leukemia 2001; 15:1941-1949.
11. Hassan R, Williams-Gould J, Watson T, et al. Pretreatment with rituximab does not inhibit the human immune response against the immunogenic protein LMB-1. Clin Cancer Res 2004; 10:16-18.
12. Lundin J, Porwit-MacDonald A, Rossmann ED, et al. Cellular immune reconstitution after subcutaneous alemtuzumab (anti-CD52 monoclonal antibody, CAMPATH-1H) treatment as first-line therapy for B-cell chronic lymphocytic leukaemia. Leukemia 2004; 18:484-490.
13. Carella AM, Beltrami G, Scalzulli PR, et al. Alemtuzumab can successfully treat steroid-refractory acute graft-versus-host disease (aGVHD). Bone Marrow Transplant 2004; 33:131-132.
14. Robak T. Alemtuzumab in the treatment of chronic lymphocytic leukemia. BioDrugs 2005; 19:9-22.
15. Laurenti L, Piccioni P, Cattani P, et al. Cytomegalovirus reactivation during alemtuzumab therapy for chronic lymphocytic leukemia: incidence and treatment with oral ganciclovir. Haematologica 2004; 89:1248-1252. One of many reports that alemtuxumab therapy is associated with an increased risk of herpesvirus infection/reactivation.
16. Lee D. Progress with alemtuzumab in chronic lymphocytic leukemia: update from the 2003 meeting of the american society of hematology. Clin Lymphoma 2004; 4:217-219.
17. Wendtner CM, Ritgen M, Schweighofer CD, et al. Consolidation with alemtuzumab in patients with chronic lymphocytic leukemia (CLL) in first remission - experience on safety and efficacy within a randomized multicenter phase III trial of the German CLL Study Group (GCLLSG). Leukemia 2004; 18:1093-1101.
18. Ghobrial IM, Otteman LA, White WL. An EBV-positive lymphoproliferative disorder after therapy with alemtuzumab. N Engl J Med 2003; 349:2570-2572; discussion.
19. Iannitto E, Minardi V, Calvaruso G, et al. Hepatitis B virus reactivation and alemtuzumab therapy. Eur J Haematol 2005; 74:254-258.
20. Peggs KS. Role of MabCampath in allogeneic transplantation. Ann Hematol 2004; 83 (Suppl. 1):S66-S68.
21. Khouri IF, Albitar M, Saliba RM, et al. Low-dose alemtuzumab (Campath) in myeloablative allogeneic stem cell transplantation for CD52-positive malignancies: decreased incidence of acute graft-versus-host-disease with unique pharmacokinetics. Bone Marrow Transplant 2004; 33:833-837. This study outlines the potential utility of Campath therapy.
22. Faulkner RD, Craddock C, Byrne JL, et al. BEAM-alemtuzumab reduced-intensity allogeneic stem cell transplantation for lymphoproliferative diseases: GVHD, toxicity, and survival in 65 patients. Blood 2004; 103:428-434. This study outlines the potential utility of Campath therapy.
23. Shenoy S, Grossman WJ, Dipersio J, et al. A novel reduced-intensity stem cell transplant regimen for nonmalignant disorders. Bone Marrow Transplant 2005; 35:345-352.
24. Thieblemont C, Bouafia F, Hornez E, et al. Maintenance therapy with a monthly injection of alemtuzumab prolongs response duration in patients with refractory B-cell chronic lymphocytic leukemia/small lymphocytic lymphoma (B-CLL/SLL). Leuk Lymphoma 2004; 45:711-714.
25. Gupta V, Ball SE, Yi QL, et al. Favorable effect on acute and chronic graft-versus-host disease with cyclophosphamide and in vivo anti-CD52 monoclonal antibodies for marrow transplantation from HLA-identical sibling donors for acquired aplastic anemia. Biol Blood Marrow Transplant 2004; 10:867-876.
26. Novitzky N, Thomas V, Stubbings H, et al. Radiotherapy-based conditioning is effective immunosuppression for patients undergoing transplantation with T-cell depleted stem cell grafts for severe aplasia. Cytotherapy 2004; 6: 450-456.
27. Gibbs SD, Herbert KE, McCormack C, et al. Alemtuzumab: effective monotherapy for simultaneous B-cell chronic lymphocytic leukaemia and Sezary syndrome. Eur J Haematol 2004; 73:447-449.
28. Avivi I, Chakrabarti S, Milligan DW, et al. Incidence and outcome of adenovirus disease in transplant recipients after reduced-intensity conditioning with alemtuzumab. Biol Blood Marrow Transplant 2004; 10:186-194. Although a report on a limited number of patients, adenovirus is frequently overlooked in adult patients.
29. Chakrabarti S, Osman H, Collingham KE, et al. Enterovirus infections following T-cell depleted allogeneic transplants in adults. Bone Marrow Transplant 2004; 33:425-430.
30. Chakrabarti S, Milligan DW, Brown J, et al. Influence of cytomegalovirus (CMV) sero-positivity on CMV infection, lymphocyte recovery and non-CMV infections following T-cell-depleted allogeneic stem cell transplantation: a comparison between two T-cell depletion regimens. Bone Marrow Transplant 2004; 33:197-204.
31. Avivi I, Chakrabarti S, Kottaridis P, et al. Neurological complications following alemtuzumab-based reduced-intensity allogeneic transplantation. Bone Marrow Transplant 2004; 34:137-142.
32. Bowie VL, Snella KA, Gopalachar AS, Bharadwaj P. Listeria meningitis associated with infliximab. Ann Pharmacother 2004; 38:58-61.
33. Shrestha RK, Stoller JK, Honari G, et al. Pneumonia due to Cryptococcus neoformans in a patient receiving infliximab: possible zoonotic transmission from a pet cockatiel. Respir Care 2004; 49:606-608.
34. Scheinfeld N. Off-label uses and side effects of infliximab. J Drugs Dermatol 2004; 3:273-284.
35. Khoury JA, Dubberke ER, Devine SM. Fatal case of protothecosis in a hematopoietic stem cell transplant recipient after infliximab treatment for graft-versus-host disease. Blood 2004; 104:3414-3415.
36. Uthman I, Kanj N, El-Sayad J, Bizri AR. Miliary tuberculosis after infliximab therapy in Lebanon. Clin Rheumatol 2004; 23:279-280.
37. Patriarca F, Sperotto A, Damiani D, et al. Infliximab treatment for steroid-refractory acute graft-versus-host disease. Haematologica 2004; 89:1352-1359.
38. Srinivasan R, Chakrabarti S, Walsh T, et al. Improved survival in steroid-refractory acute graft versus host disease after non-myeloablative allogeneic transplantation using a daclizumab-based strategy with comprehensive infection prophylaxis. Br J Haematol 2004; 124:777-786.
39. Chen HR, Ji SQ, Wang HX, et al. Humanized anti-CD25 monoclonal antibody for prophylaxis of graft-vs-host disease (GVHD) in haploidentical bone marrow transplantation without ex vivo T-cell depletion. Exp Hematol 2003; 31:1019-1025.
40. Thompson JS, Pomeroy C, Kryscio RJ, et al. Use of a T cell-specific monoclonal antibody, T10B9, in a novel allogeneic stem cell transplantation protocol for hematologic malignancy high-risk patients. Biol Blood Marrow Transplant 2004; 10:858-866.
41. Bacigalupo A. Antilymphocyte/thymocyte globulin for graft versus host disease prophylaxis: efficacy and side effects. Bone Marrow Transplant 2005; 35:225-231. A well-written, timely review.
42. Fehse N, Fehse B, Kroger N, et al. Influence of anti-thymocyte globulin as part of the conditioning regimen on immune reconstitution following matched related bone marrow transplantation. J Hematother Stem Cell Res 2003; 12:237-242.
43. Wheat LJ, Connolly P, Durkin M, et al. False-positive Histoplasma antigenemia caused by antithymocyte globulin antibodies. Transplant Infect Dis 2004; 6:23-27. Useful information for the infectious diseases specialist.
44. Min CK, Maeda Y, Lowler K, et al. Paradoxical effects of interleukin-18 on the severity of acute graft-versus-host disease mediated by CD4+ and CD8+ T-cell subsets after experimental allogeneic bone marrow transplantation. Blood 2004; 104:3393-3399.
45. Nadal E, Fowler A, Kanfer E, et al. Adjuvant interleukin-2 therapy for patients refractory to donor lymphocyte infusions. Exp Hematol 2004; 32:218-223.
46. Arber C, BitMansour A, Sparer TE, et al. Common lymphoid progenitors rapidly engraft and protect against lethal murine cytomegalovirus infection after hematopoietic stem cell transplantation. Blood 2003; 102:421-428.
47. BitMansour A, Burns SM, Traver D, et al. Myeloid progenitors protect against invasive aspergillosis and Pseudomonas aeruginosa infection following hematopoietic stem cell transplantation. Blood 2002; 100:4660-4667.
48. Ermann J, Hoffmann P, Edinger M, et al. Only the CD62L+ subpopulation of CD4+CD25+ regulatory T cells protects from lethal acute GVHD. Blood 2005; 5:2220-2226. A further definition of cellular subsets capable of modulating GVHD.
49. Zeng D, Lan F, Hoffmann P, Strober S. Suppression of graft-versus-host disease by naturally occurring regulatory T cells. Transplantation 2004; 77 (1 Suppl.):S9-S11. The first identification of T-regulatory cells, capable of modulating GVHD.
50. Jacobsohn DA. Emerging therapies for graft-versus-host disease. Expert Opin Emerg Drugs 2003; 8:323-338.
51. Pollard S. Calcineurin inhibition and disease recurrence in the hepatitis C virus-positive liver transplant recipient. Liver Int 2004; 24:402-406.
52. Watashi K, Hijikata M, Hosaka M, et al. Cyclosporin A suppresses replication of hepatitis C virus genome in cultured hepatocytes. Hepatology 2003; 38:1282-1288.
53. Nakagawa M, Sakamoto N, Enomoto N, et al. Specific inhibition of hepatitis C virus replication by cyclosporin A. Biochem Biophys Res Commun 2004; 313:42-47.
54. Marchetti O, Moreillon P, Entenza JM, et al. Fungicidal synergism of fluconazole and cyclosporine in Candida albicans is not dependent on multidrug efflux transporters encoded by the CDR1, CDR2, CaMDR1, and FLU1 genes. Antimicrob Agents Chemother 2003; 47:1565-1570.
55. Singh N, Heitman J. Antifungal attributes of immunosuppressive agents: new paradigms in management and elucidating the pathophysiologic basis of opportunistic mycoses in organ transplant recipients. Transplantation 2004; 77:795-800. A particularly cogent discussion of a renewed interest in the antifungal activity of immunosuppressive agents.
56. Onyewu C, Blankenship JR, Del Poeta M, Heitman J. Ergosterol biosynthesis inhibitors become fungicidal when combined with calcineurin inhibitors against Candida albicans, Candida glabrata, and Candida krusei. Antimicrob Agents Chemother 2003; 47:956-964.
57. Sanz-Rodriguez C, Lopez-Duarte M, Jurado M, et al. Safety of the concomitant use of caspofungin and cyclosporin A in patients with invasive fungal infections. Bone Marrow Transplant 2004; 34:13-20.
58. Steinbach WJ, Schell WA, Blankenship JR, et al. In vitro interactions between antifungals and immunosuppressants against Aspergillus fumigatus. Antimicrob Agents Chemother 2004; 48:1664-1669. Elegantly designed studies defining novel combinations of antifungal and immunosuppressant drugs.
59. Campistol JM, Gutierrez-Dalmau A, Torregrosa JV. Conversion to sirolimus: a successful treatment for posttransplantation Kaposi's sarcoma. Transplantation 2004; 77:760-762.
60. Panwalkar A, Verstovsek S, Giles FJ. Mammalian target of rapamycin inhibition as therapy for hematologic malignancies. Cancer 2004; 100:657-666.
61. Stallone G, Schena A, Infante B, et al. Sirolimus for Kaposi's sarcoma in renal-transplant recipients. N Engl J Med 2005; 352:1317-1323. Important observations, albeit in solid organ transplant recipients, regarding the potential for sirolimus to exert antitumor effects or influence immune reconstitution.
62. Blaha P, Bigenzahn S, Koporc Z, et al. The influence of immunosuppressive drugs on tolerance induction through bone marrow transplantation with costimulation blockade. Blood 2003; 101:2886-2893.
63. Blazar BR, Taylor PA, Sehgal SN, Vallera DA. Rapamycin, a potent inhibitor of T-cell function, prevents graft rejection in murine recipients of allogeneic T-cell-depleted donor marrow. Blood 1994; 83:600-609.
64. Cutler C, Antin JH. Sirolimus for GVHD prophylaxis in allogeneic stem cell transplantation. Bone Marrow Transplant 2004; 34:471-476.
65. Johnston LJ, Brown J, Shizuru JA, et al. Rapamycin (sirolimus) for treatment of chronic graft-versus-host disease. Biol Blood Marrow Transplant 2005; 11:47-55.
66. Monti P, Mercalli A, Leone BE, et al. Rapamycin impairs antigen uptake of human dendritic cells. Transplantation 2003; 75:137-145.
67. Kasper C, Sayer HG, Mugge LO, et al. Combined standard graft-versus-host disease (GvHD) prophylaxis with mycophenolate mofetil (MMF) in allogeneic peripheral blood stem cell transplantation from unrelated donors. Bone Marrow Transplant 2004; 33:65-69.
68. Dowell JA, Stogniew M, Krause D, et al. Assessment of the safety and pharmacokinetics of anidulafungin when administered with cyclosporine. J Clin Pharmacol 2005; 45:227-233.
69. Nettis E, Calogiuri G, Colanardi MC, Ferrannini A, Tursi A. Drug-induced aseptic meningitis. Curr Drug Targets Immune Endocr Metabol Disord 2003; 3:143-149.
70. Sostak P, Padovan CS, Yousry TA, et al. Prospective evaluation of neurological complications after allogeneic bone marrow transplantation. Neurology 2003; 60:842-848.
71. Chohan R, Vij R, Adkins D, et al. Long-term outcomes of allogeneic stem cell transplant recipients after calcineurin inhibitor-induced neurotoxicity. Br J Haematol 2003; 123:110-113.
72. Bartynski WS, Zeigler ZR, Shadduck RK, Lister J. Pretransplantation conditioning influence on the occurrence of cyclosporine or FK-506 neurotoxicity in allogeneic bone marrow transplantation. Am J Neuroradiol 2004; 25: 261-269. A useful observation when evaluating a patient with neurotoxicity.
73. Rubin J, Wide K, Remberger M, Gustafsson B. Acute neurological complications after hematopoietic stem cell transplantation in children. Pediatr Transplant 2005; 9:62-67.
74. Haydar AA, Denton M, West A, et al. Sirolimus-induced pneumonitis: three cases and a review of the literature. Am J Transplant 2004; 4:137-139.
75. Ozdogan O, Ratip S, Ahdab YA, et al. Causes and risk factors for liver injury following bone marrow transplantation. J Clin Gastroenterol 2003; 36: 421-426.
76. Loren AW, Porter DL, Stadtmauer EA, Tsai DE. Post-transplant lymphoproliferative disorder: a review. Bone Marrow Transplant 2003; 31:145-155.
77. Shimasaki N, Mori T, Shimada H, et al. Epstein-Barr virus-associated posttransplant lymphoproliferative disorder after a cord blood stem cell transplantation presenting with pulmonary nodules. J Pediatr Hematol Oncol 2004; 26:124-127.
78. Gruhn B, Meerbach A, Hafer R, et al. Pre-emptive therapy with rituximab for prevention of Epstein-Barr virus-associated lymphoproliferative disease after hematopoietic stem cell transplantation. Bone Marrow Transplant 2003; 31:1023-1025.
79. Endo T, Nakao S, Koizumi K, et al. Successful treatment with rituximab for autoimmune hemolytic anemia concomitant with proliferation of Epstein - Barr virus and monoclonal gammopathy in a post-nonmyeloablative stem cell transplant patient. Ann Hematol 2004; 83:114-116.
80. Clave E, Agbalika F, Bajzik V, et al. Epstein-Barr virus (EBV) reactivation in allogeneic stem-cell transplantation: relationship between viral load, EBV-specific T-cell reconstitution and rituximab therapy. Transplantation 2004; 77:76-84. This study defines the utility of viral load as a surrogate for virus-specific immune reconstitution.
81. Liu D, Tammik C, Zou JZ, et al. Effect of combined T- and B-cell depletion of allogeneic HLA-mismatched bone marrow graft on the magnitude and kinetics of Epstein-Barr virus load in the peripheral blood of bone marrow transplant recipients. Clin Transplant 2004; 18:518-524. This study defines the utility of viral load as a surrogate for virus-specific immune reconstitution.
82. Imashuku S, Teramura T, Morimoto A, et al. Prolonged hypogammaglobulinemia following rituximab treatment for post transplant Epstein-Barr virus-associated lymphoproliferative disease. Bone Marrow Transplant 2004; 33:129-130. This study reports the long-term effects of rituximab therapy.
83. Sirvent-Von Bueltzingsloewen A, Sirvent N, Morand P, Cassuto JP. Fatal central nervous system lesions emerging during anti-CD20 monoclonal antibody therapy (Rituximab) for a post transplantation Epstein Barr virus-linked lymphoma. Med Pediatr Oncol 2003; 40:408-409.